Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20940198 | 0.90 | ACHE (0.35) | SLC6A2CACNA2D1ACHEGRM5HRH3 | |
| SCHEMBL24026710 | 0.84 | SLC6A2 (0.35) | SLC6A2CACNA2D1ACHEKDM4ELMNA | |
| SCHEMBL24026619 | 0.76 | DHPS (0.36) | SLC6A2CACNA2D1KDM4ELMNANPC1 | |
| SCHEMBL24026521 | 0.72 | CACNA2D1 (0.36) | SLC6A2CACNA2D1GRM5HRH3 | |
| SCHEMBL1938008 | 0.72 | LMNA (0.34) | SLC6A2CACNA2D1ACHEHRH3KDM4E | |
| SCHEMBL11916069 | 0.69 | ACHE (0.37) | ACHEGRM5SOS1SOS2KDM4E | |
| SCHEMBL24026854 | 0.69 | NPC1 (0.41) | SLC6A2CACNA2D1ACHEGRM5KDM4E | |
| SCHEMBL24026789 | 0.68 | SLC6A2 (0.39) | SLC6A2CACNA2D1ACHEGRM5KDM4E | |
| SCHEMBL22571215 | 0.68 | HRH3 (0.39) | GRM5HRH3KDM4ENPC1GAA | |
| SCHEMBL21142674 | 0.67 | MAPT (0.47) | GRM5KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | SLC6A2 28/4885CACNA2D1 10/4885ACHE 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.